BioMarin Pharmaceuticals
BMRN
486 hedge funds and large institutions have $15.9B invested in BioMarin Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 55 funds opening new positions, 202 increasing their positions, 159 reducing their positions, and 38 closing their positions.
45% more first-time investments, than exits
New positions opened: 55 | Existing positions closed: 38
27% more repeat investments, than reductions
Existing positions increased: 202 | Existing positions reduced: 159
3% more funds holding
Funds holding: 473 → 486 (+13)
4% more capital invested
Capital invested by funds: $15.3B → $15.9B (+$580M)
0.68% less ownership
Funds ownership: 100.77% → 100.09% (-0.68%)
29% less call options, than puts
Call options by funds: $102M | Put options by funds: $144M
30% less funds holding in top 10
Funds holding in top 10: 10 → 7 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
+$75.3M |
| 2 |
State Street
Boston,
Massachusetts
|
+$68.5M |
| 3 |
TCIM
TIAA CREF Investment Management
New York
|
+$51.5M |
| 4 |
ClearBridge Investments
New York
|
+$46.3M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$45.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
-$152M |
| 2 |
BlackRock
New York
|
-$84.8M |
| 3 |
FAM
Fred Alger Management
New York
|
-$62.3M |
| 4 |
Capital Research Global Investors
Los Angeles,
California
|
-$51.4M |
| 5 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
-$31.2M |
BMRN Hedge Fund Activity: Q1 2019 in Review
486 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q1 2019, worth a combined $15.9B — up 3.8% from $15.3B a quarter earlier.
Buyers outnumbered sellers: 55 funds opened new BMRN positions and 38 closed out — a net gain of 17 holders — while 202 added to existing stakes and 159 trimmed.
The largest buyer was Jennison Associates, adding an estimated $75.3M. The largest seller was Capital International Investors, cutting an estimated $152M.
- 486 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q1 2019, up from 473 in Q4 2018.
- Funds reported $15.9B of BioMarin Pharmaceuticals stock for Q1 2019, up 3.8% quarter-over-quarter.
- 55 funds opened new BioMarin Pharmaceuticals positions in Q1 2019 and 38 closed out, a net change of +17 holders.
- The largest BioMarin Pharmaceuticals buyer in Q1 2019 was Jennison Associates, an estimated $75.3M added.
- The largest BioMarin Pharmaceuticals seller in Q1 2019 was Capital International Investors, an estimated $152M sold.
Based on aggregated 13F filings for Q1 2019.